MTOR and hepatocellular carcinoma: In the present manuscript we aimed to review the role of the mammalian target of rapamycin (mTOR) pathway in the pathogenesis and biological aggressiveness of HCC to better understand the potential clinical impact of its inhibition by currently available drugs.